A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
Trial details
- Registry ID
- NCT04620330
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as avutometinib (VS-6766) and VS-6063
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Avutometinib (VS-6766) + Defactinib in Recurrent KRAS G12V, Other KRAS and BRAF Non-Small Cell Lung CancerNCT04620330 | VSTM | Phase 2 | Completed | 2023-08-29Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |